BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19247576)

  • 1. Interstitial lung disease in polymyositis and dermatomyositis.
    Chen IJ; Jan Wu YJ; Lin CW; Fan KW; Luo SF; Ho HH; Liou LB; Tsai WP; Chen JY; Yang CH; Kuo CF; Yu KH
    Clin Rheumatol; 2009 Jun; 28(6):639-46. PubMed ID: 19247576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.
    Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF
    Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.
    Kang EH; Lee EB; Shin KC; Im CH; Chung DH; Han SK; Song YW
    Rheumatology (Oxford); 2005 Oct; 44(10):1282-6. PubMed ID: 15972351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis].
    Wang PZ; Guan JL; Han XH
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun; 31(6):417-20. PubMed ID: 19031800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.
    Li T; Tang ZY; Zhang QB; Xiao FN; Jian GL; Xie Y; Guo JW; Qing YF
    Curr Rheumatol Rev; 2023; 19(4):455-462. PubMed ID: 37005523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictive factors and unfavorable prognostic factorial analysis of interstitial lung disease in patients with inflammatory myopathy].
    Li R; Li XP; Li XM; Wang GS; Qian L; Tao JH; Ma Y; Zhang H
    Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(33):2335-8. PubMed ID: 23158563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis.
    Zhang L; Wu G; Gao D; Liu G; Pan L; Ni L; Li Z; Wang Q
    PLoS One; 2016; 11(5):e0155381. PubMed ID: 27171228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial lung disease in polymyositis and dermatomyositis.
    Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H
    Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020.
    Sun KY; Fan Y; Wang YX; Zhong YJ; Wang GF
    Semin Arthritis Rheum; 2021 Feb; 51(1):175-191. PubMed ID: 33383294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of antineutrophil cytoplasmic antibody positivity on the occurrence of interstitial lung disease in patients with polymyositis/dermatomyositis.
    Ha JW; Pyo JY; Ahn SS; Song JJ; Park YB; Lee SW
    Ann Palliat Med; 2022 Oct; 11(10):3181-3192. PubMed ID: 36226644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
    Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
    Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
    Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
    PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.
    Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF
    Arthritis Rheum; 2011 Nov; 63(11):3439-47. PubMed ID: 21702020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
    Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.